Since patients who were treated with anti-CTLA-4 therapy were included in the TCGA melanoma dataset, we performed the Kaplan-Meier (KM) survival analysis by excluding them separately (Supplementary Materials and Methods) and found similar result (Fig. S15F). This evidence concerns the gene CTLA4 and melanoma.